Remove 2028 Remove Dosage Remove Packaging
article thumbnail

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

Express Pharma

As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. In March 2024, Lonza hosted its first digital Responsible Supplier Event which brought together more than 1,100 participants.

Dosage 104
article thumbnail

N-FIS was developed to address a critical challenge in healthcare—needle phobia

Express Pharma

Key parameters, such as pressure and orifice size, are carefully calibrated to achieve accurate drug delivery at the desired depth and dosage, making it a safe and efficient alternative to traditional needle injections. billion in 2028, growing at a compound annual growth rate (CAGR) of 14.16

article thumbnail

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

PharmaTech

billion and an additional $2 billion in non-contingent anniversary payments through 2028. billion (1). billion (1). This news comes just 10 days after BioNTech announced a global co-development and co-commercialization agreement valued at up to $11.1 billion for BNT327 (2). BioNTech is also eligible to receive up to $7.6 References 1.

Dosage 52